Phage Displayed Peptides/Antibodies Recognizing Growth Factors and Their Tyrosine Kinase Receptors as Tools for Anti-Cancer Therapeutics

International Journal of Molecular Sciences

Roberto Ronca²  Patrizia Benzoni¹  Angela De Luca¹  Elisabetta Crescini¹ 

[1] Fibroblast Reprogramming Unit, Department of Biomedical Sciences and Biotechnology, viale Europa, 11, 25123 Brescia, Italy; E-Mails:;Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, viale Europa, 11, 25123 Brescia, Italy; E-Mail:

关键词: phage display;    humanized antibody;    growth factors;    tyrosine kinase receptors;    anticancer therapy;   

DOI  :  10.3390/ijms13045254

来源: mdpi

【 摘 要 】

The basic idea of displaying peptides on a phage, introduced by George P. Smith in 1985, was greatly developed and improved by McCafferty and colleagues at the MRC Laboratory of Molecular Biology and, later, by Barbas and colleagues at the Scripps Research Institute. Their approach was dedicated to building a system for the production of antibodies, similar to a naïve B cell repertoire, in order to by-pass the standard hybridoma technology that requires animal immunization. Both groups merged the phage display technology with an antibody library to obtain a huge number of phage variants, each of them carrying a specific antibody ready to bind its target molecule, allowing, later on, rare phage (one in a million) to be isolated by affinity chromatography. Here, we will briefly review the basis of the technology and the therapeutic application of phage-derived bioactive molecules when addressed against key players in tumor development and progression: growth factors and their tyrosine kinase receptors.

【 授权许可】

CC BY   
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.